ArticleClinical & experimental metastasis2012
hMLH1 promoter hypermethylation and MSI status in human endometrial carcinomas with and without metastases.
Article in Clinical & experimental metastasis, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- The role of hypoxia-senescence co-related molecular subtypes and prognostic characteristics in hepatocellular carcinoma.Scientific reports · 2025Article
- Research Progress of DNA Methylation in Endometrial Cancer.Biomolecules · 2022Review
- Development of novel quality control material based on CRISPR/Cas9 editing and xenografts for MLH1 protein deficiency testing.Journal of clinical laboratory analysis · 2021Article
- The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer.Frontiers in oncology · 2020Review
- Epigenetic mechanisms and the hallmarks of cancer: an intimate affair.American journal of cancer research · 2020Review
- MLH1 deficiency leads to deregulated mitochondrial metabolism.Cell death & disease · 2019Article
- Article
- Recent findings on epigenetic gene abnormalities involved in uterine cancer.Molecular and clinical oncology · 2017Article
- Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer.International journal of oncology · 2017Article
- Biomarkers of genome instability and cancer epigenetics.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Expression level and methylation status of three tumor suppressor genes, DLEC1, ITGA9 and MLH1, in non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2016Article
- DNA methylation and cancer diagnosis.International journal of molecular sciences · 2013Review
- Emerging therapeutic biomarkers in endometrial cancer.BioMed research international · 2013Review
- Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the methylation status of mismatch repair gene hMLH1 in 80 primary human endometrial carcinomas (ECs) and in 30 metastatic lesions. It was correlated to the expression of hMLH1 protein, microsatellite instability (MSI) of ECs and to the well-known clinico-pathological variables of cancer. The hMLH1 promoter methylation was detected in 24 out of 64 (37.5 %) primary ECs but only in one out of 18 (5.6 %) metastatic lesions investigated. Promoter hMLH1 hypermethylation was found more often in early stage ECs and was associated with a decrease of hMLH1 protein expression immunohistochemically. An inverse relationship between hMLH1 expression and clinical stage of the disease was found (p = 0.048). Interestingly, there was a significant correlation between MSI and hMLH1 protein expression level (p = 0.042). MSI phenotype was found more often in EC metastases compared to the primary tumors (66.7 % vs 29.3 %; p = 0.039). However, neither hMLH1 promoter hypermethylation nor MSI was independent predictive factors for patient's outcome. Using an in vitro model we showed that hMLH1 methylation is reversible. These data showed that hMLH1 methylation with a consequent protein decrease occurred early during EC tumorigenesis and may cause a MSI phenotype, which occurs relatively late. MSI may be an important mechanism supporting further the tumor progression. These findings may have importance for the specific chemosensitization of the primary tumors/metastases and can improve our understanding of endometrial carcinogenesis in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.